Drug Type Antibody drug conjugate (ADC) |
Synonyms BB 204, BB204 |
Target |
Action antagonists, inhibitors |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), Tumor-associated antigen inhibitors(Tumor-associated antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Bladder Cancer | Preclinical | United States | 15 May 2024 | |
| Lung Cancer | Preclinical | United States | 15 May 2024 | |
| Uterine Cervical Cancer | Preclinical | United States | 15 May 2024 |






